Microsoft and Syneos Health, a top provider of fully integrated biopharmaceutical solutions, have announced a strategic multi-year cooperation.
Syneos Health has created an advanced analytics platform with Microsoft Azure services that enables flexible machine learning (ML) deployment to assist the research, design, and execution of clinical trials and commercial initiatives globally.
The multi-year agreement utilizes developments from OpenAI and collaborates with Microsoft Research.
Under this partnership, Syneos Health and Microsoft will offer technology and data solutions that speed up clinical development and improve commercial performance for clients in the biopharmaceutical industry.
Syneos Health is able to handle and analyze data based on this AI-enabled platform to expedite timelines, optimize resource allocation, and unleash clinical trial efficiency.
Better site selection and shorter enrollment periods made possible by these skills may hasten the introduction of novel medicines for patients.
Microsoft is the perfect technology partner for Syneos Health, according to CEO Michelle Keefe. Their realistic approach to enhancing healthcare outcomes for patients, science, and industry is entirely in line with our value offer. They have a clear industry leadership in AI. We anticipate having a solid connection for many years to come, one that inspires creative ways to hasten the success of our clients.
Also Read: https://thecitizenscoop.com/powerful-medical-announced-the-launch-of-pmcardio-in-the-uk/
Microsoft Vice President of U.S. Health and Life Sciences Patty Obermaier stated, “We are happy to work with Syneos Health to combine our expertise in AI along with their solutions to help make a real difference in the lives of patients. By combining Azure Synapse Analytics, Azure Data Factory, Azure SQL Database, and other Azure services, Syneos Health is able to create a platform that enables its biopharma clients to provide treatments to patients more quickly.
